pharmaphorum3d
GSK eyes nasal polyps use for Nucala after trial success
GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into competition ...
pharmaphorum6y
FDA rejects GSK's Nucala in COPD, asking for more clinical data
The US regulator has rejected GlaxoSmithKline's pulmonary disease drug Nucala in a potential new chronic obstructive pulmonary disease (COPD) use. In July, Nucala (mepolizumab), which is already ...
Hosted on MSN12d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
Hosted on MSN15d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...
Yahoo Finance15d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been ... type 2 inflammation-related diseases. More about GlaxoSmithKline GSK is a global biopharmaceutical company dedicated ...
The Pharma Letter15d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
Daily15d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
Future Market Insights1d
Global Nasal Allergy Treatment Market to Reach USD 13.3 Billion by 2033 at a CAGR of 6.7% | Data by Future Market Insights, Inc.
According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...
Business Insider16d
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK)) has provided an update ... Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with ...
Business Insider16d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...
Nasdaq15d
GSK’s Nucala Gains Approval in China for CRSwNP
More about GlaxoSmithKline GSK is a global biopharmaceutical company dedicated to combining science, technology, and talent to advance healthcare. It has a leading respiratory portfolio and is ...